Latest Close
$4.19
News
NGEN
NervGen Pharma Corp. News
This news view pulls recent coverage and headlines tied to NGEN.
1y Change
$2.04 (+94.88%)
Market Cap
$339,100,352.00
Sector
Healthcare
Industry
Biotechnology
Recommendation
buy
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire • Apr 13, 2026
Read articleNervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
GlobeNewswire • Apr 7, 2026
Read articleNervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
GlobeNewswire • Mar 31, 2026
Read articleNervGen Pharma to Voluntarily Delist From TSX Venture Exchange on March 16
MT Newswires • Mar 13, 2026
Read articleNervGen Pharma to Delist From TSX Venture Exchange
MT Newswires • Mar 12, 2026
Read articleNervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
GlobeNewswire • Mar 12, 2026
Read article